Reports Q4 revenue $2.30B, consensus $2.3B. CEO Kewalramani says: "Outstanding execution across the company resulted in another year of strong revenue growth as well as acceleration of both the research and clinical-stage pipeline. Our progress in 2022 lays the foundation for treating more people with cystic fibrosis, launching multiple new therapies in the near term, achieving important clinical milestones, and driving continued significant growth for many years to come."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex options imply 3.7% move in share price post-earnings
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
- Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler
- Vertex Pharmaceuticals initiated with a Hold at Canaccord
- SVB Securities upgrades Vertex to Outperform, raises price target to $374